ARK Invest's position in MDWD, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| IZRL | 133,672 | $1.7M | 1.45% | #47 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-12 | IZRL | Sell | Trimmed | 29,354 | $381K |
| 2026-10-15 | IZRL | Buy | Added | 20,497 | $250K |
| 2026-07-16 | IZRL | Buy | Added | 21,590 | $315K |
| 2026-04-16 | IZRL | Sell | Trimmed | 3,385 | $58K |
| 2026-01-15 | IZRL | Buy | Added | 20,310 | $353K |
| 2025-10-16 | IZRL | Buy | Added | 4,023 | $78K |
| 2025-07-18 | IZRL | Buy | Added | 2,277 | $47K |
| 2025-07-17 | IZRL | Buy | Added | 5,390 | $108K |
| 2025-04-17 | IZRL | Sell | Trimmed | 4,208 | $72K |
| 2025-01-17 | IZRL | Buy | Added | 6,684 | $118K |
| 2024-10-21 | IZRL | Buy | Added | 15,771 | $270K |
| 2024-07-19 | IZRL | Buy | New position | 99,994 | $1.9M |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals…
See MDWD's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open MDWD on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.